Study of the Safety, Tolerability and Efficacy of BTX 1204 in Patients With Moderate Atopic Dermatitis

Status:
Completed

Trial end date:
2020-03-04

Target enrollment:

Participant gender:

This is a randomized, double-blind, vehicle-controlled, Phase 2 study in subjects with moderate AD.

Phase 2

Botanix Pharmaceuticals